Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Dose-ranging, Safety, Pharmacokinetics, and Preliminary Efficacy Study of MPB-1734 in Patients With Advanced Solid Tumors in Part 1 and With Selected Solid Tumors in Part 2

NCT04643418 is registered in ClinicalTrials.gov with MegaPro Biomedical Co. Ltd. as lead sponsor.

NCT NCT04643418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04643418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Dose-ranging, Safety, Pharmacokinetics, and Preliminary Efficacy Study of MPB-1734 in Patients With Advanced Solid Tumors in Part 1 and With Selected Solid Tumors in Part 2
Lead sponsor
MegaPro Biomedical Co. Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 8, 2022
Completion date
December 31, 2025
Enrollment
81 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, unspecified, adult